Specify a stock or a cryptocurrency in the search bar to get a summary
Skye Bioscience, Inc. Common Stock
SKYESkye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. Address: 11250 El Camino Real, San Diego, CA, United States, 92130
Analytics
WallStreet Target Price
18 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SKYE
Dividend Analytics SKYE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SKYE
Stock Valuation SKYE
Financials SKYE
Results | 2019 | Dynamics |